NeurAxis, Inc. (NRXS)
:NRXS
NRXS Stock Chart & Stats
$7.25
-$0.04(-1.54%)
At close: 4:00 PM EST
$7.25
-$0.04(-1.54%)
Day’s Range― - ―
52-Week Range$1.33 - $7.97
Previous CloseN/A
Volume9.85K
Average Volume (3M)55.04K
Market Cap
$81.11M
Enterprise Value$76.56M
Total Cash (Recent Filing)$4.97M
Total Debt (Recent Filing)$416.61K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 27, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding11,187,639
10 Day Avg. Volume34,967
30 Day Avg. Volume55,039
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)12.13
Price to Sales (P/S)11.55
P/FCF Ratio-6.38
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue21.45
Enterprise Value/Gross Profit25.47
Enterprise Value/Ebitda-9.99
Forecast
1Y Price Target
$13.00Price Target Upside79.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$8.50M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthConsistent double-digit unit and revenue growth combined with very high gross margins (~84% TTM) indicate durable unit economics and product pricing power. This mix supports scalable gross-profit generation as volumes rise, enabling margin retention if operating spend is disciplined while commercialization scales.
Structural Reimbursement & Coverage WinsSecuring a Category I CPT code and a combined coverage footprint >100M (plus major payer policy and VA FSS access) creates a durable reimbursement framework. This materially reduces access friction for providers, underpins repeatable billing workflows and enables a sales-led scaling strategy across payers and institutional channels over the medium term.
Manageable Leverage And Improved LiquidityLow reported leverage and recent financings that raised cash to >$6M provide financial flexibility to fund commercial expansion and ongoing trials. A stabilized equity position versus prior periods reduces solvency risk, giving management runway to execute reimbursement and commercialization plans without immediate reliance on large dilutive raises.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow at multi-million dollar annualized levels creates a structural need for external capital to fund operations and growth. Ongoing cash burn increases dilution risk, constrains strategic optionality, and forces prioritization between commercialization investments and clinical evidence generation unless revenue scale accelerates materially.
Rising Operating Expenses And LossesIncreasing sales, R&D and G&A spend has elevated fixed cost base and widened operating losses. These commercialization-driven expense trends lengthen the runway to operating leverage and require sustained, above-trend revenue growth to achieve profitability, making execution on scaling utilization and payer wins critical for long-term margin recovery.
Uneven Institutional Adoption And Delayed Adult CoverageAdoption is top‑heavy and hampered by institutional barriers (committee approvals, lack of champions), limiting near-term throughput. Broader adult payer policies depend on a large RCT (estimated ~18 months), meaning material portions of the addressable market may remain inaccessible until trial results and subsequent policy updates occur.
NeurAxis, Inc. News
NRXS FAQ
What was NeurAxis, Inc.’s price range in the past 12 months?
NeurAxis, Inc. lowest stock price was $1.33 and its highest was $7.97 in the past 12 months.
What is NeurAxis, Inc.’s market cap?
NeurAxis, Inc.’s market cap is $81.11M.
When is NeurAxis, Inc.’s upcoming earnings report date?
NeurAxis, Inc.’s upcoming earnings report date is May 27, 2026 which is in 52 days.
How were NeurAxis, Inc.’s earnings last quarter?
NeurAxis, Inc. released its earnings results on Mar 19, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.215 by $0.035.
Is NeurAxis, Inc. overvalued?
According to Wall Street analysts NeurAxis, Inc.’s price is currently Undervalued.
Does NeurAxis, Inc. pay dividends?
NeurAxis, Inc. does not currently pay dividends.
What is NeurAxis, Inc.’s EPS estimate?
NeurAxis, Inc.’s EPS estimate is -0.2.
How many shares outstanding does NeurAxis, Inc. have?
NeurAxis, Inc. has 11,187,639 shares outstanding.
What happened to NeurAxis, Inc.’s price movement after its last earnings report?
NeurAxis, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.215. Following the earnings report the stock price went up 2.432%.
Which hedge fund is a major shareholder of NeurAxis, Inc.?
Currently, no hedge funds are holding shares in NRXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeurAxis, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (79.31% Upside)
$13.00 (79.31% Upside)
Insider Transactions
Bought Shares
Worth $32.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.07%
12-Months-Change
Fundamentals
Return on Equity
-3071.15%
Trailing 12-Months
Asset Growth
405.25%
Trailing 12-Months
Company Description
NeurAxis, Inc.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
NRXS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a clear progression from regulatory and coverage milestones toward commercialization: a Category I CPT code, a ~45M member major payer policy, an FSS contract with the VA, sustained unit and revenue growth, and strengthened liquidity. Management also outlined concrete commercial hiring and payer engagement plans and multiple ongoing clinical trials to expand adult and other-indication coverage. Offsetting these positives are margin compression driven by product mix and inventory adjustments, higher operating expenses that increased quarterly losses, uneven hospital adoption due to operational/administrative barriers, and the need for additional payer policies (and an adult RCT) to unlock broader adoption. Overall, the upside from reimbursement wins, regulatory progress, accelerating submissions and funded runway meaningfully outweighs the execution and margin challenges in the near term.View all NRXS earnings summariesNRXS Stock 12 Month Forecast
Average Price Target
$13.00
▲(79.31% Upside)
Technical Analysis
Ownership Overview
3.90% Insiders
1.42% Mutual Funds
10.79% Other Institutional Investors
82.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---